De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

被引：0
|
作者：
Dennen, Syvart
Shao, Anran
Dennen, Syvart
Cockrum, Paul
Paluri, Ravi Kumar
机构：
[1] Genesis Res, Hoboken, NJ USA
[2] Ipsen Biopharmaceut Inc, Cambridge, MA USA
[3] Wake Forest Baptist Hlth, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
130-544; 130-3426-5390-2622-5397; 613-135-244-3829-325-11291; 261-2394; 130-540-543-11341; 2; 1699; 239; 16; 193; 1692; 54; 1700; 8; 6; 4; 3;
D O I：
10.1200/JCO.2024.42.3_suppl.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：628 / 628
页数：1
相关论文
共 50 条
  • [41] Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Elias, Rawad
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    Shahrokni, Armin
    ONCOLOGIST, 2022, 27 (06): : 469 - 475
  • [42] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [43] Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice
    Yadav, Budhi Singh
    Dey, Treshita
    RADIATION ONCOLOGY JOURNAL, 2023, 41 (04): : 237 - 247
  • [44] Real-world safety data and differentiation of second-line (2L) 5-fluorouracil (5-FU) based regimens among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Kim, George P.
    Cockrum, Paul
    Chudnovsky, Aleksander
    Surinach, Andy
    Wainberg, Zev A.
    Wang Shu
    Yakubu, Amin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen.
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Abushahin, Laith, I
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [46] REAL-WORLD "CHAIR-TIME" BURDEN ASSOCIATED WITH INTRAVENOUS TREATMENT REGIMENS FOR PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    MacEwan, J.
    Surinach, A.
    Lamarre, N.
    Cockrum, P.
    VALUE IN HEALTH, 2022, 25 (07) : S326 - S326
  • [47] Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (US).
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Koeller, Jim M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
    Taieb, Julien
    Hammel, Pascal
    Reni, Michele
    Palmer, Daniel H.
    Bridgewater, John A.
    Cubillo, Antonio
    Prager, Gerald W.
    Vermeire, Alice
    D'Esquermes, Nathalie
    Biville-Hedouin, Fabienne
    Teng Zhaoyang
    Seufferlein, Thomas
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [49] TREATMENT OUTCOMES AND PREDICTORS OF DISEASE FLARE IN PATIENTS WITH ULCERATIVE COLITIS UNDERGOING TOFACITINIB DOSE DE-ESCALATION: A REAL-WORLD EXPERIENCE
    Yu, Amy
    Shi, Bingyan
    Ha, Nghiem B.
    Cheng, Yao-Wen
    Beck, Kendall
    GASTROENTEROLOGY, 2023, 164 (06) : S1134 - S1134
  • [50] Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes
    Wattenberg, Max M.
    Smith, Karin Enell
    de Coana, Yago Pico
    Jimenez, David Gomez
    Carlsson, Malin
    Ambarkhane, Sumeet Vijay
    Ellmark, Peter
    Beatty, Gregory L.
    CANCER RESEARCH, 2024, 84 (02)
12345